Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
Mark J A SchoonderwoerdMaaike F M KoopsRicardo A AngelaBryan KoolmoesMelpomeni ToitouMadelon PaauweMarieke C BarnhoornYingmiao LiuCornelis F M SierJames C H HardwickAndrew B NixonCharles P TheuerMarieke F FransenLukas J A C HawinkelsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Taken together, these data provide a rationale for combining TRC105 and anti-PD1 therapy and provide additional evidence of endoglin's immunomodulatory role.